caa a22 4500 469116056 CHVBK 20180323133125.0 cr unu---uuuuu 170328e19921201xx s 000 0 eng 10.1007/BF02755881 doi (NATIONALLICENCE)springer-10.1007/BF02755881 Conditional pharmacology: II. Ambivalent effects of aurocyanide, a putative active metabolite of anti-arthritic gold drugs, on human and rat PMN leucocytes [Elektronische Daten] [S. Gadd, M. Whitehouse, B. Vernon-Roberts] Aurocyanide, and to a lesser extent, aurothiomalate and aurothiosulphate, showed diverse antioxidant/pro-oxidant effects on PMN leucocytes when stimulated ex-vivo to generate hydrogen peroxide. In normal human cells, aurocyanide inhibited peroxide production (ID50 for aurocyanideca. 5 μmol/L) and reduced average cell size more potently than the thiomalate and thiosulphate (ID50 of 200 μmol/L for both). Factors influencing the results included the type of fluorochrome for detecting peroxide and intrinsic variability between human donors. In the presence of azide (1 mmol/L), peroxide production was stimulated but cell size was still reduced. Some PMN stimulants such as fMLP and complement component C5a with aurocyanide only stimulated peroxide production in the presence of azide and had no effect in its absence. In both normal and arthritic rat neutrophils, aurocyanide only stimulated peroxide production but still reduced cell size. These observations show that mechanisms of action of these gold drugs may be related to the effects of aurocyanide but there are differences between rat and human cells in vitro. A single dose of aurocyanide (10 mg/kg) co-administered with two arthritogenic adjuvants effectively prevented arthritis development in rats. Much higher doses, bordering on toxic, were required for two gold-thiolates to exhibit similar activity. Kluwer Acedemic Publishers, 1992 aurocyanide nationallicence aurothiomalate nationallicence aurothiosulphate nationallicence anti-arthritic gold drugs nationallicence peroxide nationallicence Gadd S. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut Whitehouse M. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut Vernon-Roberts B. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut InflammoPharmacology Birkhäuser-Verlag 1/4(1992-12-01), 305-314 0925-4692 1:4<305 1992 1 10787 https://doi.org/10.1007/BF02755881 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02755881 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gadd S. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut NATIONALLICENCE 700 1- Whitehouse M. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut NATIONALLICENCE 700 1- Vernon-Roberts B. Department of Pathology, University of Adelaide, 5001, Adelaide, South Australia, Australia aut NATIONALLICENCE 773 0- InflammoPharmacology Birkhäuser-Verlag 1/4(1992-12-01), 305-314 0925-4692 1:4<305 1992 1 10787 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer